Cancer is a major cause of morbidity and mortality throughout the world and in spite of recent advances in molecular pathogenesis of cancer, it still remains an enigmatic disease. It is estimated that there were more than 1.2 million new cases of cancer (excluding nonmelanoma skin cancers and carcinoma in situ of cervix), and 564000 deaths from cancer in 1998 in the United States. Now it is becoming increasingly clear that cancer is an extraordinarily diverse disease caused not only by chemicals but also by bacteria, viruses, parasites, metals and hormones. Cancer causing agents can be classified as direct and indirect carcinogens. Direct (genotoxic) carcinogens induce tumors by altering the genetic information of cells, (chemicals and radiation through DNA damage resulting in somatic mutations and the presence of transforming genes as in some viruses), whereas indirect (nongenotoxic) carcinogens induce tumors through a variety of biological effects. Peroxisome proliferators are a diverse group of synthetic and naturally occurring compounds that are of therapeutic, industrial and agricultural value. We discovered the liver tumor inducing properties of this diverse class of important chemicals and showed that they are nongenotoxic. We hypothesize that oxygen free radicals produced by peroxisome proliferator activated receptor alpha (PPARalpha) mediated increases in peroxisomal fatty acid beta-oxidation and other hydrogen peroxide generating enzymes will lead to DNA damage and increased cell proliferation resulting in hepatocarcinogenesis. To fully evaluate the role of oxidative stress and cell proliferation in peroxisome proliferator-induced hepatocarcinogenesis we will utilize mice deficient in fatty acyl-CoA oxidase (AOX), deficient in PPARalpha and deficient in both AOX and PPARalpha.
The specific aims i nclude: 1) analysis of hepatocarcinogenesis in AOX null mice by examining the effect of natural activators of PPARalpha and critically evaluating the role of apoptosis and cell proliferation; 2) assess the role of sustained activation of PPARalpha and steatohepatitis in the development of liver tumors in AOX null mice by ascertaining the tumor chemopreventive potential of nonsteroidal antiinflammatory agents; 3) examine the role of PPARalpha and AOX in peroxisome proliferator induced pleiotropic responses by studying (PPARalpha) and AOX double null mice; 4) critical analysis of the role of oxidative stress in hepatocarcinogenesis induced by steatohepatitis resulting from deficiency of dietary factors, and 5) evaluation of the role of growth factors and cell cycle proteins in hepatocarcinogenesis induced by dietary factors and ciprofibrate in rats and spontaneous tumors in AOX null mice. The anticipation is that elucidation of mechanistic aspects of hepatocarcinogenesis induced by peroxisome proliferators, the prototype of nongenotoxic carcinogens, will not only enable the identification of factors responsible for a large majority of human tumors, usually referred to as 'spontaneous tumors' but also help to develop new therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA084472-03
Application #
6497960
Study Section
Chemical Pathology Study Section (CPA)
Program Officer
Poland, Alan P
Project Start
2000-02-01
Project End
2005-01-31
Budget Start
2002-02-01
Budget End
2003-01-31
Support Year
3
Fiscal Year
2002
Total Cost
$242,685
Indirect Cost
Name
Northwestern University at Chicago
Department
Pathology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Mo, Rigen; Rao, Sambasiva M; Zhu, Yi-Jun (2006) Identification of the MLL2 complex as a coactivator for estrogen receptor alpha. J Biol Chem 281:15714-20
Jia, Yuzhi; Qi, Chao; Zhang, Zhongyi et al. (2005) Peroxisome proliferator-activated receptor-binding protein null mutation results in defective mammary gland development. J Biol Chem 280:10766-73
Qi, Chao; Zhu, Yiwei Tony; Chang, Jeffrey et al. (2005) Potentiation of estrogen receptor transcriptional activity by breast cancer amplified sequence 2. Biochem Biophys Res Commun 328:393-8
Yu, Songtao; Viswakarma, Navin; Batra, Surinder K et al. (2004) Identification of promethin and PGLP as two novel up-regulated genes in PPARgamma1-induced adipogenic mouse liver. Biochimie 86:743-61
Qi, Chao; Kashireddy, Papreddy; Zhu, Yiwei Tony et al. (2004) Null mutation of peroxisome proliferator-activated receptor-interacting protein in mammary glands causes defective mammopoiesis. J Biol Chem 279:33696-701
Bu, Hengfu; Kashireddy, Papreddy; Chang, Jeffrey et al. (2004) ERBP, a novel estrogen receptor binding protein enhancing the activity of estrogen receptor. Biochem Biophys Res Commun 317:54-9
Qi, Chao; Surapureddi, Sailesh; Zhu, Yi-Jun et al. (2003) Transcriptional coactivator PRIP, the peroxisome proliferator-activated receptor gamma (PPARgamma)-interacting protein, is required for PPARgamma-mediated adipogenesis. J Biol Chem 278:25281-4
Meyer, Kirstin; Lee, Ju-Seog; Dyck, Patricia A et al. (2003) Molecular profiling of hepatocellular carcinomas developing spontaneously in acyl-CoA oxidase deficient mice: comparison with liver tumors induced in wild-type mice by a peroxisome proliferator and a genotoxic carcinogen. Carcinogenesis 24:975-84
Jia, Yuzhi; Qi, Chao; Zhang, Zhongyi et al. (2003) Overexpression of peroxisome proliferator-activated receptor-alpha (PPARalpha)-regulated genes in liver in the absence of peroxisome proliferation in mice deficient in both L- and D-forms of enoyl-CoA hydratase/dehydrogenase enzymes of peroxisomal beta-ox J Biol Chem 278:47232-9
Yu, Songtao; Matsusue, Kimihiko; Kashireddy, Papreddy et al. (2003) Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem 278:498-505

Showing the most recent 10 out of 27 publications